User menu

Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.

Bibliographic reference Lambein, Kathleen ; Van Bockstal, Mieke ; Vandemaele, Lies ; Van den Broecke, Rudy ; Cocquyt, Veronique ; et. al. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.. In: Virchows Archiv : an international journal of pathology, (2017)
Permanent URL http://hdl.handle.net/2078.1/186913
  1. Allred D.Craig, Clark Gary M., Molina Rafael, Tandon Atul K., Schnitt Stuart J., Gilchrist Kennedy W., Osborne C.Kent, Tormey Douglass C., McGuire William L., Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer, 10.1016/0046-8177(92)90257-4
  2. Barnes D.M., Smith P.J., Millis R.R., Bartkova J., Camplejohn R.S., Gullick W.J., Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?, 10.1016/s0959-8049(05)80117-0
  3. Barnes N. L.P., Absence of HER4 Expression Predicts Recurrence of Ductal Carcinoma In situ of the Breast, 10.1158/1078-0432.ccr-04-1633
  4. Barros Fabrício F T, Powe Desmond G, Ellis Ian O, Green Andrew R, Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments, 10.1111/j.1365-2559.2010.03494.x
  5. Bryan Bradley B, Schnitt Stuart J, Collins Laura C, Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer, 10.1038/modpathol.3800570
  6. Burkhardt L., Grob T. J., Hermann I., Burandt E., Choschzick M., Jänicke F., Müller V., Bokemeyer C., Simon R., Sauter G., Wilczak W., Lebeau A., Gene amplification in ductal carcinoma in situ of the breast, 10.1007/s10549-009-0675-8
  7. Castellana Bàrbara, Escuin Daniel, Peiró Gloria, Garcia-Valdecasas Bárbara, Vázquez Tania, Pons Cristina, Pérez-Olabarria Maitane, Barnadas Agustí, Lerma Enrique, ASPN and GJB2 Are Implicated in the Mechanisms of Invasion of Ductal Breast Carcinomas, 10.7150/jca.4120
  8. Doebar S.C., de Monyé C., Stoop H., Rothbarth J., Willemsen S.P., van Deurzen C.H.M., Ductal carcinoma in situ diagnosed by breast needle biopsy: Predictors of invasion in the excision specimen, 10.1016/j.breast.2016.02.014
  9. Doebar Shusma C., van den Broek Esther C., Koppert Linetta B., Jager Agnes, Baaijens Margreet. H. A., Obdeijn Inge-Marie A. M., van Deurzen Carolien H. M., Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study, 10.1007/s10549-016-3862-4
  10. ELSTON C.W., ELLIS I.O., pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, 10.1111/j.1365-2559.1991.tb00229.x
  11. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC, American Society of Clinical O, College of American P (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (unabridged version). Arch Pathol Lab Med 134:e48–e72. doi: 10.1043/1543-2165-134.7.e48
  12. Hammond M. Elizabeth, Hayes Daniel F., Wolff Antonio C., Clinical Notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer, 10.1200/jco.2011.35.2245
  13. Han K., Nofech-Mozes S., Narod S., Hanna W., Vesprini D., Saskin R., Taylor C., Kong I., Paszat L., Rakovitch E., Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence, 10.1016/j.clon.2011.09.008
  14. Harvey Jennet M., Clark Gary M., Osborne C. Kent, Allred D. Craig, Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer, 10.1200/jco.1999.17.5.1474
  15. Hernandez Lucia, Wilkerson Paul M, Lambros Maryou B, Campion-Flora Adriana, Rodrigues Daniel Nava, Gauthier Arnaud, Cabral Cecilia, Pawar Vidya, Mackay Alan, A'Hern Roger, Marchiò Caterina, Palacios Jose, Natrajan Rachael, Weigelt Britta, Reis-Filho Jorge S, Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection, 10.1002/path.3990
  16. Holmes Phoebe, Lloyd Joshua, Chervoneva Inna, Pequinot Edward, Cornfield Dennis B., Schwartz Gordon F., Allen Kathleen G., Palazzo Juan P., Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone, 10.1002/cncr.25942
  17. Iakovlev V. V., Arneson N. C.R., Wong V., Wang C., Leung S., Iakovleva G., Warren K., Pintilie M., Done S. J., Genomic Differences Between Pure Ductal Carcinoma In Situ of the Breast and that Associated with Invasive Disease: a Calibrated aCGH Study, 10.1158/1078-0432.ccr-07-4960
  18. Jang Min Hye, Kim Eun Joo, Choi Yoomi, Lee Hee Eun, Kim Yu Jung, Kim Jee Hyun, Kang Eunyoung, Kim Sung-Won, Kim In Ah, Park So Yeon, FGFR1 is amplified during the progression of in situto invasive breast carcinoma, 10.1186/bcr3239
  19. Kerlikowske K., Molinaro A. M., Gauthier M. L., Berman H. K., Waldman F., Bennington J., Sanchez H., Jimenez C., Stewart K., Chew K., Ljung B. M., Tlsty T. D., Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis, 10.1093/jnci/djq101
  20. Kim Sun-Ah, Cho Nariya, Ryu Eun Bi, Seo Mirinae, Bae Min Sun, Chang Jung Min, Moon Woo Kyung, Background Parenchymal Signal Enhancement Ratio at Preoperative MR Imaging: Association with Subsequent Local Recurrence in Patients with Ductal Carcinoma in Situ after Breast Conservation Surgery, 10.1148/radiol.13130459
  21. Kulkarni Swati, Patil Deepa B, Diaz Leslie K, Wiley Elizabeth L, Morrow Monica, Khan Seema A, COX-2 and PPARγ expression are potential markers of recurrence risk in mammary duct carcinoma in-situ, 10.1186/1471-2407-8-36
  22. Lambein K., Praet M., Forsyth R., Van den Broecke R., Braems G., Matthys B., Cocquyt V., Denys H., Pauwels P., Libbrecht L., Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations, 10.1136/jcp.2010.084863
  23. Lambein Kathleen, Van Bockstal Mieke, Denys Hannelore, Libbrecht Louis, 2013 Update of the American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing: Impact on Immunohistochemistry-Negative Breast Cancers, 10.1200/jco.2013.54.2530
  24. Lambein K., Van Bockstal M., Vandemaele L., Geenen S., Rottiers I., Nuyts A., Matthys B., Praet M., Denys H., Libbrecht L., Distinguishing Score 0 From Score 1+ in HER2 Immunohistochemistry-Negative Breast Cancer: Clinical and Pathobiological Relevance, 10.1309/ajcp4a7ktayhzsoe
  25. Lee S., Stewart S., Nagtegaal I., Luo J., Wu Y., Colditz G., Medina D., Allred D. C., Differentially Expressed Genes Regulating the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer, 10.1158/0008-5472.can-12-0636
  26. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O’Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E, Members of the Cancer Committee CoAP (2009) Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 133:1515–1538. doi: 10.1043/1543-2165-133.10.1515
  27. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O’Malley FP, Page DL, Smith BL, Weaver DL, Winer E, Members of the Cancer Committee CoAP (2009) Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med 133:15–25. doi: 10.1043/1543-2165-133.1.15
  28. Leung Cheuk T., Brugge Joan S., Outgrowth of single oncogene-expressing cells from suppressive epithelial environments, 10.1038/nature10826
  29. Lin Shili, Mixture modeling of progression pathways of heterogeneous breast tumors, 10.1016/j.jtbi.2007.08.010
  30. Lu Jing, Guo Hua, Treekitkarnmongkol Warapen, Li Ping, Zhang Jian, Shi Bin, Ling Chen, Zhou Xiaoyan, Chen Tongzhen, Chiao Paul J., Feng Xinhua, Seewaldt Victoria L., Muller William J., Sahin Aysegul, Hung Mien-Chie, Yu Dihua, 14-3-3ζ Cooperates with ErbB2 to Promote Ductal Carcinoma In Situ Progression to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal Transition, 10.1016/j.ccr.2009.08.010
  31. Ma Xiao-Jun, Dahiya Sonika, Richardson Elizabeth, Erlander Mark, Sgroi Dennis C, Gene expression profiling of the tumor microenvironment during breast cancer progression, 10.1186/bcr2222
  32. Moelans Cathy B, van Diest Paul J, CEP17 copy number increase does not indicate polysomy 17, 10.1136/jclinpath-2013-202104
  33. Muthuswamy Senthil K., Li Dongmei, Lelievre Sophie, Bissell Mina J., Brugge Joan S., ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini, 10.1038/ncb0901-785
  34. Nofech-Mozes Sharon, Spayne Jacqueline, Rakovitch Eileen, Hanna Wedad, Prognostic and Predictive Molecular Markers in DCIS : A Review, 10.1097/01.pap.0000184177.65919.5e
  35. Nofech-Mozes S, Spayne J, Rakovitch E, Kahn HJ, Seth A, Pignol JP, Lickley L, Paszat L, Hanna W (2008) Biological markers predictive of invasive recurrence in DCIS. Clin Med Oncol 2:7–18
  36. Noh Jae Myoung, Lee Jihae, Choi Doo Ho, Cho Eun Yoon, Huh Seung Jae, Park Won, Nam Seok Jin, Lee Jeong Eon, Kil Won-Ho, HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy, 10.1016/j.breast.2013.04.001
  37. Park K, Han S, Kim H J, Kim J, Shin E, HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry, 10.1111/j.1365-2559.2006.02403.x
  38. Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C, COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features, 10.1111/j.1365-2559.2005.02132.x
  39. Pradeep C-R, Zeisel A, Köstler W J, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y, Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions, 10.1038/onc.2011.547
  40. Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, Spayne J, Taylor C, Paszat L, HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ, 10.1038/bjc.2012.41
  41. Rane Swapnil Ulhas, Mirza Hasan, Grigoriadis Anita, Pinder Sarah E., Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis, 10.1007/s10549-015-3509-x
  42. Ross Dara S., Wen Yong Hannah, Brogi Edi, Ductal Carcinoma In Situ : Morphology-Based Knowledge and Molecular Advances, 10.1097/pap.0b013e3182976ed5
  43. Rüschoff Josef, Lebeau Annette, Kreipe Hans, Sinn Peter, Gerharz Claus Dieter, Koch Winfried, Morris Stefanie, Ammann Johannes, Untch Michael, Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany, 10.1038/modpathol.2016.164
  44. Sauter Guido, Lee James, Bartlett John M.S., Slamon Dennis J., Press Michael F., Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations, 10.1200/jco.2007.14.8197
  45. Poller D.N., Barth A., Slamon D.J., Silverstein M.J., Gierson E.D., Coburn W.J., Waisman J.R., Gamagami P., Lewinsky B.S., Prognostic classification of breast ductal carcinoma-in-situ, 10.1016/s0140-6736(95)90982-6
  46. Siziopikou Kalliopi P., Ductal Carcinoma In Situ of the Breast: Current Concepts and Future Directions, 10.5858/arpa.2012-0078-ra
  47. Siziopikou Kalliopi P., Anderson Stewart J., Cobleigh Melody A., Julian Thomas B., Arthur Douglas W., Zheng Ping, Mamounas Eleftherios P., Pajon Eduardo R., Behrens Robert J., Eakle Janice F., Leasure Nick C., Atkins James N., Polikoff Jonathan A., Seay Thomas E., McCaskill-Stevens Worta J., Rabinovitch Rachel, Costantino Joseph P., Wolmark Norman, Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43, 10.1007/s10549-013-2755-z
  48. Siziopikou Kalliopi P., Khan Saba, Correlation of HER2 Gene Amplification With Expression of the Apoptosis-Suppressing Genes bcl-2 and bcl-x-L in Ductal Carcinoma in Situ of the Breast : , 10.1097/00129039-200503000-00003
  49. Solin L. J., Gray R., Baehner F. L., Butler S. M., Hughes L. L., Yoshizawa C., Cherbavaz D. B., Shak S., Page D. L., Sledge G. W., Davidson N. E., Ingle J. N., Perez E. A., Wood W. C., Sparano J. A., Badve S., A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast, 10.1093/jnci/djt067
  50. Sontag Laura, Axelrod David E., Evaluation of pathways for progression of heterogeneous breast tumors, 10.1016/j.jtbi.2004.08.002
  51. Van Bockstal Mieke, Lambein Kathleen, Denys Hannelore, Braems Geert, Nuyts Ann, Van den Broecke Rudy, Cocquyt Veronique, De Wever Olivier, Libbrecht Louis, Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype, 10.1007/s00428-014-1609-3
  52. Van Bockstal Mieke, Lambein Kathleen, Gevaert Olivier, De Wever Olivier, Praet Marleen, Cocquyt Veronique, Van den Broecke Rudy, Braems Geert, Denys Hannelore, Libbrecht Louis, Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinomain situof the breast, 10.1111/his.12188
  53. Wolff Antonio C., Hammond M. Elizabeth H., Hicks David G., Dowsett Mitch, McShane Lisa M., Allison Kimberly H., Allred Donald C., Bartlett John M.S., Bilous Michael, Fitzgibbons Patrick, Hanna Wedad, Jenkins Robert B., Mangu Pamela B., Paik Soonmyung, Perez Edith A., Press Michael F., Spears Patricia A., Vance Gail H., Viale Giuseppe, Hayes Daniel F., Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update, 10.5858/arpa.2013-0953-sa
  54. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology/College of American P (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18–43. doi: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2